Drug Profile
CLX 090502
Latest Information Update: 27 Oct 2005
Price :
$50
*
At a glance
- Originator Calyx Therapeutics (CEASED)
- Class Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Rheumatoid arthritis
Most Recent Events
- 25 Oct 2005 Discontinued - Preclinical for Inflammation in USA (PO)
- 25 Oct 2005 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
- 29 Jan 2003 Preclinical trials in Inflammation in USA (PO)